{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:06:06Z","timestamp":1788678366104,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lanmic.2026.101442","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:24:15Z","timestamp":1785353055000},"page":"101442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines"],"prefix":"10.1016","author":[{"given":"Ben J","family":"Marais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-4376","authenticated-orcid":false,"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tiberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Yeboah-Manu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-2684","authenticated-orcid":false,"given":"Sayoki","family":"Mfinanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S","family":"Nyasulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Chakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Ntoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Walzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-2445","authenticated-orcid":false,"given":"David S","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-5735","authenticated-orcid":false,"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101442_bib3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(25)02433-X","article-title":"Global tuberculosis response off track: urgent priorities to end the world's top infectious killer","volume":"407","author":"Hui","year":"2025","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.lanmic.2026.101442_bib4","article-title":"Inequities underlie the alarming resurgence of tuberculosis as the world's top cause of death from an Infectious Disease\u2014Breaking the silence and addressing the underlying root causes","volume":"14","author":"Zumla","year":"2025","journal-title":"IJID Reg"},{"key":"10.1016\/j.lanmic.2026.101442_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12879-025-10863-0","article-title":"Barriers and facilitators to pediatric tuberculosis management in India: a systematic review","volume":"25","author":"Willis","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S2213-2600(24)00028-6","article-title":"Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise","volume":"12","author":"Coussens","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(25)00555-0","article-title":"Asymptomatic tuberculosis: undetected and underestimated, but not unimportant","volume":"405","author":"Dheda","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101442_bib9","doi-asserted-by":"crossref","first-page":"e1869","DOI":"10.1016\/S2214-109X(25)00276-1","article-title":"Screening for asymptomatic tuberculosis among adults with household exposure to pulmonary tuberculosis: a prospective observational cohort study","volume":"13","author":"Mendelsohn","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101442_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/QCO.0000000000001156","article-title":"New drugs for the management of tuberculosis","volume":"38","author":"Cross","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib11","article-title":"Update in tuberculosis treatment: a scoping review of current practices","volume":"21","author":"Lopes","year":"2025","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.lanmic.2026.101442_bib12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s40121-025-01221-3","article-title":"A new era in tuberculosis prevention and treatment: breakthroughs in drug development and future prospects","volume":"14","author":"Zhao","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.lanmic.2026.101442_bib21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B\u22123, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S1473-3099(25)00151-3","article-title":"Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial","volume":"25","author":"Paton","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1473-3099(25)00436-0","article-title":"A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial","volume":"26","author":"Metcalfe","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1473-3099(24)00223-8","article-title":"Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial","volume":"24","author":"Cevik","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-026-02734-w","article-title":"Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: a randomized trial","author":"Gao","year":"2026","journal-title":"Infection"},{"key":"10.1016\/j.lanmic.2026.101442_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(24)00601-7","article-title":"Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial","volume":"25","author":"Dawson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib32","first-page":"1100","article-title":"Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis","volume":"2","year":"1974","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.lanmic.2026.101442_bib33","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib34","first-page":"171","article-title":"Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101442_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2019.103937","article-title":"Evolution of rifampicin treatment for tuberculosis","volume":"74","author":"Grobbelaar","year":"2019","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.lanmic.2026.101442_bib36","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1093\/infdis\/jiaf069","article-title":"Azithromycin as host-directed therapy for pulmonary tuberculosis: a randomized pilot trial","volume":"231","author":"Dekkers","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/cid\/ciae193","article-title":"Clinical outcomes in children with human immunodeficiency virus treated for nonsevere tuberculosis in the SHINE trial","volume":"79","author":"Chabala","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","article-title":"Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial","volume":"7","author":"Tweed","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lanmic.2026.101442_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2026.04.004","article-title":"Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2\/3 randomized clinical trial","author":"Li","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2026.101442_bib41","article-title":"Post-tuberculosis lung disease","volume":"22","author":"Al-Hindawi","year":"2026","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.lanmic.2026.101442_bib42","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1097\/QCO.0000000000001163","article-title":"Post-tuberculosis lung disease in people with HIV: a scoping and narrative review","volume":"39","author":"Wills","year":"2026","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa2212537","article-title":"Treatment strategy for rifampin-susceptible tuberculosis","volume":"388","author":"Paton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib45","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3201\/eid3103.241634","article-title":"Efficacy and safety of 4-month rifapentine-based tuberculosis treatments in persons with diabetes","volume":"31","author":"Kurbatova","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib48","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/cid\/ciab1037","article-title":"Efavirenz pharmacokinetics and human immunodeficiency virus type 1 (HIV-1) viral suppression among patients receiving tuberculosis treatment containing daily high-dose rifapentine","volume":"75","author":"Podany","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae178","article-title":"Experience with four-month rifapentine and moxifloxacin-based tuberculosis treatment in San Francisco","volume":"11","author":"Louie","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5588\/ijtld.24.0616","article-title":"Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen","volume":"29","author":"Galvis","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib52","article-title":"Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"51","author":"Cheraghi","year":"2025","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.lanmic.2026.101442_bib53","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1093\/cid\/ciaf112","article-title":"Treatment outcomes with an oral short course regimen for rifampicin-resistant tuberculosis in a high HIV prevalence, programmatic setting in South Africa","volume":"81","author":"Stadler","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11904-022-00641-x","article-title":"Evidence for implementation: management of TB in HIV and pregnancy","volume":"19","author":"Jones","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.lanmic.2026.101442_bib55","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2214-109X(25)00431-0","article-title":"Global estimates of tuberculosis incidence during pregnancy and postpartum: a rapid review and modelling analysis","volume":"14","author":"Mafirakureva","year":"2026","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101442_bib56","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3018(25)00040-2","article-title":"Tuberculosis disease among people with HIV: therapeutic advances","volume":"12","author":"Mave","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.lanmic.2026.101442_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf503","article-title":"Intensified treatment of tuberculous meningitis in adults: a systematic review and meta-analysis","volume":"12","author":"Llamas-Lopez","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib60","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib61","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMoa2502866","article-title":"Trial of high-dose oral rifampin in adults with tuberculous meningitis","volume":"393","author":"Meya","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib62","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMoa2216218","article-title":"Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults","volume":"389","author":"Donovan","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib63","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S1473-3099(25)00364-0","article-title":"A clinical practice guideline for tuberculous meningitis","volume":"26","author":"Donovan","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib64","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-025-04138-z","article-title":"Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial","volume":"32","author":"Donovan","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf450","article-title":"Standardized infliximab regimen to treat severe central nervous system tuberculosis: a case series of 18 patients","volume":"12","author":"Benhard","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib66","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s12879-025-11072-5","article-title":"DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis","volume":"25","author":"Tukvadze","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib67","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1186\/s12879-025-11503-3","article-title":"The impact of digital adherence technologies on treatment outcomes, adherence, and patient-reported outcomes in tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib68","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1016\/S2214-109X(23)00308-X","article-title":"Digital adherence technologies in tuberculosis","volume":"11","author":"Hafez","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101442_bib69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101442_bib70","article-title":"Use of infliximab to treat paradoxical tuberculous meningitis reactions","volume":"8","author":"Marais","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib71","article-title":"Tuberculous meningitis with paradoxical reaction in an immunocompetent young male treated by interleukin-1 receptor antagonist","volume":"2025","author":"Kanat","year":"2025","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004437","article-title":"Fighting tuberculosis hand in hand: a call to engage communities affected by TB as essential partners in research","volume":"5","author":"Venkatesan","year":"2025","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.lanmic.2026.101442_bib72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12883-024-03701-4","article-title":"Efficacy and safety of intrathecal dexamethasone combined with isoniazid in the treatment of tuberculous meningitis: a meta-analysis","volume":"24","author":"Gao","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.lanmic.2026.101442_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5588\/ijtld.17.0486","article-title":"Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges","volume":"22","author":"Swindells","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib75","doi-asserted-by":"crossref","first-page":"814","DOI":"10.5588\/ijtld.21.0098","article-title":"Challenges in recruiting children to a multidrug-resistant TB prevention trial","volume":"25","author":"Purchase","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib77","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5588\/ijtld.18.0885","article-title":"Access to experimental medicines for TB: ethical and human rights considerations","volume":"24","author":"Dagron","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lanmic.2026.101442_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jme-2023-109234","article-title":"Exploring the ethics of tuberculosis human challenge models","volume":"52","author":"Rohrig","year":"2026","journal-title":"J Med Ethics"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:52:49Z","timestamp":1785358369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"alternative-id":["S2666524726000972"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101442","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101435","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101443","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101433","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101442"}}